Downing Fellow using AI to re-analyse clinical trial for Alzheimer's medicine
Professor Zoe Kourtzi, Downing Fellow in Cognitive Neuroscience, has led a study using an AI model to reassess the results of a completed clinical trial for an Alzheimer's disease drug.
Using the purpose-built AI tool, the study found that the drug slowed down the rate of cognitive decline by 46% in a group of patients with early-stage, slow-progressing mild cognitive impairment – a condition that can progress to Alzheimer’s.
The results of the study have been published in the journal Nature Communications.
Professor Kourtzi said: “Promising new drugs fail when given to people too late, when they have no chance of benefiting from them. With our AI model, we can finally identify patients precisely and match the right patients to the right drugs. This makes trials more precise, so they can progress faster and cost less, turbocharging the search for a desperately-needed precision medicine approach for dementia treatment."
Published 25 July 2025